CD8A and neoplasm: Considering that an important percentage of both CD4+ and CD8+ tumor-infiltrating T cells expressed PD-1 in the anti-DEC-205:16E5-treated mice, we tested whether an anti-PD-1 blocking mAb could increase mice survival.